Improving Medication-taking After Liver Transplant (I-AM)

Mount Sinai Health System

Status and phase

Completed

Phase 1

Conditions

Tacrolimus

Nonadherence

Pediatric Liver Transplant Recipients

Treatments

Behavioral: Telemetric

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01960322

GCO 13-0223

Details and patient eligibility

About

The specific aim is to pilot-test our developed intervention manual's ability to improve patients' adherence to medications and medical outcomes (rejection rate, liver enzyme levels) in participating centers.

Full description

Nonadherence (not taking the medications as prescribed) is the most common cause of late acute rejection in children who have had a liver transplant, and thus is associated with graft loss, increased expenditures on care, and ultimately death. Researchers in this application developed a biomarker to identify nonadherence, calculating the standard deviation (SD) of consecutive immunosuppressant blood levels for each patient to capture the degree of variability between individual levels (higher SD = less consistent levels). By applying a threshold, this marker identifies nonadherent patients. A consortium of transplant centers is currently testing this marker through the MALT (Medication Adherence in children who had a Liver Transplant) study. MALT investigators now propose to take advantage of this existing collaboration to pilot-test an intervention to improve adherence in patients who are identified by this marker.

Enrollment

7 patients

Sex

All

Ages

11 to 19 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The patient is between 11-19 years of age at enrollment.
Guardian's consent, child assent (in accordance with each institution's IRB policies).
The patient is prescribed tacrolimus (either brand or generic formulation).
The patient has been seen in the enrolling center's clinic at least once in the last two years.
The patient's SD of tacrolimus was > 2.0 in the year prior to enrollment, with at least 3 levels present to make this determination.
The patient and at least one guardian speaks English or Spanish at a level that allows her / him to understand the study procedures and consent to the study.

Exclusion criteria

The patient received a liver transplant less than 1 year prior to enrollment.
The patient has had more than one transplant (including marrow replacement).
The patient has had biopsy-proven rejection within the past six months.
The patient has been diagnosed with Hepatitis C.
The treating physician has instructed the patient not to obtain tacrolimus levels for at least one year in the past year.
The guardian or child (in a developmentally-appropriate manner) do not understand the study procedures. This will be verified by asking both guardian and child to repeat the study procedures.
The patient is only seen for consultation - most or all of the child's routine care is provided at another center (or in a community clinic).
Either the patient or the guardian is actively psychotic or severely disoriented due to any cause, including hepatic encephalopathy (temporary exclusion) or severely mentally retarded as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV).
The patient is not medically stable or is hospitalized.